Abstract
Pyrazoloacridine (PZA) is the first of a new class of rationally synthesized acridine derivatives to undergo clinical testing as an anticancer agent. Recent studies suggest that PZA might be a dual inhibitor of DNA topoisomerase I and DNA topoisomerase II that exerts its effects by diminishing the formation of topoisomerase-DNA adducts. Consistent with this unique mechanism of action, PZA exhibits broad spectrum antitumor activity in preclinical models in vivo. In addition, this agent displays several unique properties including solid tumor selectivity, activity against hypoxic cells, and cytotoxicity in noncycling cells. PZA also retains full activity against cells that are resistant to other agents on the basis of overexpression of P-glycoprotein or the multidrug resistance-associated protein (MRP). PZA has been studied in phase I trials in adults and children, and is currently undergoing broad phase II trials in a number of tumor types. No significant anti-tumor activity has been seen in gastrointestinal malignancies and prostate cancer. Results from ongoing or recently completed trials are awaited before the utility of this agent in our current armamentarium can be defined. Because of its unique properties, combination studies with other antineoplastic agents are warranted.
Similar content being viewed by others
References
Jackson R, Sebolt J, Shillis J: The pyrazoloacridines: approaches to the development of a carcinoma-selective cytotoxic agent. Cancer Inv 8: 39–47, 1990
Capps D, Ross-Kesten S, Shillis J, Plowman J: 2-aminoalkyl-5-nitropyrazolo[3,4,5-k] acridines, a new class of anticancer agents (abstract). Proc Am Assoc Cancer Res 27: 277, 1986
Sebolt J, Scavone S, Pinter C: Pyrazoloacridines, a new class of antitumor agents with selectivity against solid tumors in vitro. Cancer Res 47: 4299–4304, 1987
LoRusso P, Wozniak AJ, Polin L: Antitumor efficacy of PD 115932 (NSC 366140) against solid tumors of mice. Cancer Res 50: 4900–4905, 1990
Sebolt J, Havlick M, Hamelehle K: Activity of the pyrazoloacridines against multidrug-resistant tumor cells. Cancer Chemother Pharmacol 24: 219–224, 1989
Cole SPC: Patterns of cross-resistance in a multidrugresistance small cell lung carcinoma line. Cancer Chemother Pharmacol 26: 250–256, 1990
Sebolt-Leopold JS, Scavone SV: Biochemistry of the interactions between DNA and the pyrazoloacridines, a series of 48 biologically novel anticancer agents. Proc Am Assoc Cancer Res 32: 334, 1991
Grem JL, Politi PM, Berg SL, Benchekroun NM, Patel M, Balis FM, Sinha BK, Dahut W, Allegra CJ: Cytotoxicity and DNA damage associated with pyrazolaacridine in MCF-7 breast cancer cells. Biochem Pharmacol 51(12): 1648–1659, 1996
Adjei AA, Charron M, Rowinsky EK, Svingen PA, Miller J, Reid JM, Sebolt-Leopold J, Ames MM, Kaufmann SH: Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res 4(3): 683–691, 1998
Berg SL, Balis FM, McCully CL, Godwin KS, Poplack DG: Pharmacokinetics of pyrazoloacridine in the rhesus monkey. Cancer Res 51(20): 5467–5470, 1991
Rowinsky EK, Noe DA, Grochow LB, Sartorious SE, Bowling MK, Chen T-L, Lubejko BG, Kaufmann SH, Donehower RC: Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single and multiple dosing schedules. J Clin Oncol 13: 1975–1984, 1995
LoRusso P, Foster BJ, Poplin E, McCormick J, Kraut M, Flaherty L, Heilbrun LK, Valdivieso M, Baker L: Phase I clinical trial of pyrazoloacridine NSC 366140 (PD 115934). Clin Cancer Res 1: 1487–1493, 1995
Monahan B, Quinn M, Takimoto C et al.: Phase I trial of pyrazoloacridine (PZA), a potent DNA binding agent, given as a weekly 24 hour continuous intravenous infusion in adult patients with refractory solid tumors. Proc Amer Soc Clin Oncol 17: 736, 1998
Berg SL, Blaney SM, Adamson PC, O'Brien M, Poplack DG, Arndt C, Blatt J, Balis FM: Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers. J Clin Oncol 16(1): 181–186, 1998
Murgo AJ, Cannon D, Christian MC, Cheson B, Nelson AP: Clinical trials referral resource. Clinical trials with pyrazoloacridine. Oncology 11(7): 991–994, 1997
Zalupski MM, Shields AF, Philip PA, Kraut M, LoRusso P, Heilbrun LK, Vaitkevicius V: Evaluation of pyrazoloacridine in patients with advanced pancreatic carcinoma. Invest New Drugs (16(1): 93–96, 1998
Small EJ, Fippin LJ, Whisenant SP: Pyrazoloacridine for the treatment of hormone-refractory prostate cancer. Cancer Invest 16(7): 456–461, 1998
Zalupski MM, Philip PA, LoRusso P, Shields AF: Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma. Cancer Chemother & Pharmacol 40(3): 225–227, 1997
Mani S, Gerstner JB, Wade JL, Kugler JW et al.: Phase II trials of pyrazoloacridine (NSC 366140) in patients with advanced hepatobiliary and pancreatic cancer. Cancer Therapeutics 1: 313–317, 1998
Adjei AA, Budihardjo I, Rowinsky EK et al.: Cytotoxic synergy between pyrazoloacridine (NSC 366140) and cisplatin in vitro: Inhibition of platinum-DNA adduct removal. Clin Cancer Res 4: 683–691, 1998
Adjei AA, Kaufman SH, Reid J, Sloan JA, Alberts SR, Goldberg RM, Erlichman C: A phase I study of pyrazoloacridine (PZA) and carboplatin (CBDCA) in patients with advanced solid tumors. Proc Amer Assoc Cancer Res 39: 2206, 1998
Jackson RC: The problem of the quiescent cancer cell. Adv Enzyme Reg 29: 27–46, 1989
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Adjei, A.A. Current status of pyrazoloacridine as an anticancer agent. Invest New Drugs 17, 43–48 (1999). https://doi.org/10.1023/A:1006242321596
Issue Date:
DOI: https://doi.org/10.1023/A:1006242321596